The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

Ian Crosbie joins Sequana Medical as Chief Financial Officer

Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative, implantable pump systems that manage fluid build-up occurring in patients with liver disease, heart disease and certain cancers, announced today the appointment of Ian Crosbie as Chief Financial Officer.

“We are delighted to welcome Ian to Sequana Medical. He is an excellent choice for Chief Financial Officer, with 25 years of experience, both in-house at medical device and pharmaceutical companies, and as an investment banker at several leading global firms. His expertise and strong track record in capital markets, licensing and strategic transactions strengthens the management team and will be instrumental in both the strategic positioning of Sequana and the successful commercialization of the alfapump® system for patients with liver disease globally, as well as the expansion of our pump technology to the management of fluid overload in advanced heart failure,” stated Noel L. Johnson, Ph.D., Chief Executive Officer of Sequana Medical.

“Sequana Medical has developed and started commercializing an elegant, yet simple solution to the problem of chronic fluid overload inside the body – thereby solving a major medical problem with few therapeutic options and significantly improving patient quality of life and reducing healthcare costs. I believe strongly in the value proposition that this Company represents and look forward to working with the entire management team and Board to reach our operational and financial objectives,” said Ian Crosbie.

Prior to joining Sequana Medical, Mr. Crosbie was Chief Financial Officer of GC Aesthetics Ltd. based in Dublin. Before that, Mr. Crosbie was Senior Vice President, Corporate Development at Circassia Pharmaceuticals plc, a late-stage biopharmaceutical company focused on allergy immunotherapy where he led the execution of the company’s ₤210 million IPO, as well as the M&A & licensing activities. Prior to Circassia, Mr. Crosbie enjoyed a 20-year career in corporate finance, including Managing Director, Healthcare Investment Banking at Jefferies International Limited and Director, Healthcare Investment Banking at Deutsche Bank. In addition he was a founding partner at Gargoyle Partners / Ferghana Partners.

Mr. Crosbie served as a Second Lieutenant in the 32nd Armoured Engineer Regiment of the British Army and earned a degree in Engineering, Economics and Management from Oxford University.

Download the full press release.

Related Posts



    We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

    The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.